A British national working in the Democratic Republic of Congo has tested positive for the Bundibugyo strain of Ebola, and is being airlifted back to the United Kingdom for treatment. The patient is reported to be stable and is expected to arrive in the UK on Wednesday or Thursday. While the risk to the British public remains low, the case has intensified global efforts to develop vaccines and treatments for this particularly lethal virus.
The British patient and evacuation arrangements
The healthcare worker, whose identity has not been disclosed, was deployed to the DRC by a humanitarian organisation to assist with the response to the outbreak. A Foreign Office spokesperson confirmed, “A British citizen currently in the DRC has tested positive for Ebola. The risk to the UK public from Ebola remains low.”
Medical evacuation plans are already in place. The patient will be transported by air to a specialist centre in the UK, where they will receive advanced supportive care. Officials have indicated that the transfer will occur as soon as a suitable aircraft is secured, with arrival anticipated early in the week following the positive test.
Vaccine breakthroughs targeting Bundibugyo
The World Health Organization (WHO) has identified the rVSVΔG/BDBV‑GP vaccine, developed by the International AIDS Vaccine Initiative (IAVI), as the most promising candidate for preventing Bundibugyo infection. This single‑dose vaccine, which builds on the same platform used for Merck’s Ervebo product against the Zaire strain, demonstrated protection in non‑human primates during a 2023 proof‑of‑concept study. WHO officials estimate that the vaccine could be ready for formal clinical‑trial assessment within seven to nine months.
Another candidate, ChAdOx1 Bundibugyo, is being advanced by Oxford University and the Serum Institute of India. Leveraging the ChAdOx1 technology that underpinned the Oxford‑AstraZeneca COVID‑19 vaccine, this formulation is being manufactured under an emergency response framework. Production began shortly after the outbreak was reported in May, and the WHO indicated that doses could be available for efficacy testing within two to three months, pending further animal studies.
In addition, the WHO’s Technical Advisory Group has recommended that Moderna’s mRNA‑1469 and the IAVI rVSV vaccine enter the pivotal Phase 2/3 clinical trial in the DRC. This marks the first inclusion of Bundibugyo‑specific vaccines in a large‑scale trial, a step that could accelerate the generation of efficacy data and bring new tools to bear on the epidemic.
Experimental therapeutics and antiviral options
Antibody‑based treatments are also being fast‑tracked. Mapp Biopharmaceutical’s MBP134, a combination of two human monoclonal antibodies initially tested against Sudan ebolavirus, has shown safety in early‑stage trials and is now being prepared for clinical evaluation among confirmed Bundibugyo cases. The U.S. Biomedical Advanced Research and Development Authority (BARDA) is coordinating the shipment of the investigational product for potential use among high‑risk American contacts.
Regeneron Pharmaceuticals’ maftivimab, another monoclonal antibody, has demonstrated activity against the Bundibugyo virus in laboratory settings. The company is preparing existing supplies for upcoming trials after the WHO recommended it be studied as a monotherapy.
Researchers are also exploring antibodies derived from survivors of Bundibugyo infection. The candidate BDBV289‑N, isolated from a convalescent patient, provided up to 100 % protection in monkeys even when treatment was initiated up to eight days after exposure, according to a 2018 NIH‑supported study.
On the antiviral front, Gilead Sciences’ oral drug obeldesivir is under consideration for post‑exposure prophylaxis. Preclinical data suggest that a once‑daily regimen over ten days can protect monkeys from both Zaire and Sudan ebolavirus when started within 24 hours of exposure, and the company believes the compound may retain activity against Bundibugyo.
Remdesivir, administered intravenously, has shown activity against the Bundibugyo strain in laboratory studies conducted by the University of Texas Medical Branch. Some analyses indicate it may be more potent against Bundibugyo than against the Zaire variant. A trial launched in early July in Ituri province, the outbreak’s epicentre, is now enrolling participants, led by Congo’s National Institute for Biomedical Research together with France’s ANRS Emerging Infectious Diseases and several humanitarian partners.
The WHO has called for a combination therapy that pairs a monoclonal antibody with remdesivir for evaluation, aiming to leverage the strengths of both approaches and improve outcomes for patients.
Testing challenges and response coordination
Limited diagnostic capacity has hampered the response to the Bundibugyo outbreak. To address this, BioFire Defense, a subsidiary of bioMérieux, has expanded production of its FDA‑cleared BioFire Global Fever Special Pathogens Panel, which can detect multiple Ebola species, including Bundibugyo. The company has increased manufacturing and engaged with public health authorities to meet anticipated demand.
Altona Diagnostics, based in Germany, has supplied its RealStar Filovirus Screen RT‑PCR Kit 1.0 to Congolese testing sites, enabling the detection of the Bundibugyo strain. The firm has ramped up output to support local laboratories in the affected provinces.
Clinical trials for experimental antivirals are already underway. The trial in Ituri province, supported by ALIMA, Médecins Sans Frontières and other organisations, began enrolling participants in July. These studies will generate crucial safety and efficacy data for the investigational drugs being considered.
Why it Matters
The emergence of the first British Ebola case underscores how quickly a virus once confined to remote regions can cross borders, threatening global health security. Accelerating the development and deployment of safe, effective vaccines and treatments is essential not only to protect those on the front lines but also to prevent future international spread. Successful trials of Bundibugyo‑specific candidates could fill a critical gap in the global medical arsenal, offering a new line of defence against a disease that has already claimed more than 5,000 lives and infected over 10,000 people, with a fatality rate that can reach 40 % in this strain. The coordinated effort by WHO, research institutions, pharmaceutical companies and humanitarian organisations reflects a decisive shift toward a more proactive, science‑driven response, and may ultimately save countless lives both in the DRC and beyond.
